

**Coca-Cola Europacific Partners plc (the "Company")**  
**Transactions in Own Shares and Programme Update**

The Company confirms that on 27 March 2025 it purchased a total of: (i) 65,125 ordinary shares of EUR 0.01 ("**ordinary shares**") on the US Trading Venues<sup>[1]</sup> and (ii) 0 ordinary shares on the London Trading Venues<sup>[2]</sup>; in both cases, from Goldman Sachs & Co. LLC, Goldman Sachs International or one of their affiliates, as detailed below.

The repurchased ordinary shares will be cancelled.

The purchases form part of the Company's share buyback programme announced on 14 February 2025 (the "**Programme**"). In connection with the Programme, the Company expects to repurchase up to EUR 1 billion of ordinary shares (in aggregate). The Company announced on 14 February 2025 that the aggregate amount for purchases in respect of the initial tranche of the Programme (expected to be completed by 23 May 2025) is EUR 275,00,000, of which EUR 55,000,000 would be in respect of the London Trading Venues. The Company today announces that whilst the aggregate amount in respect of the initial tranche remains the same, the amount in respect of the London Trading Venues has been increased from EUR 55,000,000 to EUR 67,000,000 (with purchases on the London Trading Venues expected to be completed by 16 May 2025, as previously announced).

	<b>US Trading Venues</b>	<b>London Stock Exchange</b>	<b>CBOE Europe Limited (CXE)</b>	<b>CBOE Europe Limited (BXE)</b>	<b>Aquis</b>
Date of purchase	27 March 2025	27 March 2025	27 March 2025	27 March 2025	27 March 2025
Aggregate number of ordinary shares purchased	65,125	0	0	0	0
Highest price paid (per ordinary share)	USD 86.3900	GBP 0	GBP 0	GBP 0	GBP 0
Lowest price paid (per ordinary share)	USD 85.4000	GBP 0	GBP 0	GBP 0	GBP 0
Volume weighted average price paid (per ordinary share)	USD 85.9856	GBP 0	GBP 0	GBP 0	GBP 0

This announcement does not constitute, or form part of, an offer or solicitation of an offer for securities in any jurisdiction.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), full details of the transactions, are set out in the Schedule to this announcement available through the link below:

[http://www.rns-pdf.londonstockexchange.com/rns/5961C\\_1-2025-3-27.pdf](http://www.rns-pdf.londonstockexchange.com/rns/5961C_1-2025-3-27.pdf)

## CONTACTS

**Company Secretariat**  
**Clare Wardle**  
[clare.wardle@ccep.com](mailto:clare.wardle@ccep.com)

**Investor Relations**  
**Sarah Willett**  
[sarah.willett@ccep.com](mailto:sarah.willett@ccep.com)

**Media Relations**  
**Shanna Wendt**  
[mediaenquiries@ccep.com](mailto:mediaenquiries@ccep.com)

## ABOUT CCEP

Coca-Cola Europacific Partners is one of the world's leading consumer goods companies. We make, move and sell some of the world's most loved brands - serving nearly 600 million consumers and helping over 4 million customers across 31 countries grow.

We combine the strength and scale of a large, multi-national business with an expert, local knowledge of the customers we serve and communities we support.

The Company is currently listed on Euronext Amsterdam, NASDAQ (and a constituent of the Nasdaq 100), London Stock Exchange and on the Spanish Stock Exchanges, trading under the symbol CCEP.

For more information about CCEP, please visit [www.cocacolaep.com](http://www.cocacolaep.com) and follow CCEP on [LinkedIn](#)

---

[1] The "US Trading Venues" comprise Nasdaq and other applicable US trading venues.

[2] The "London Trading Venues" comprise the London Stock Exchange, CBOE Europe Limited (BXE), CBOE Europe Limited (CXE) and Aquis. Goldman Sachs acquired CREST Depositary Interests on the London Trading Venues, which will be cancelled together with the underlying shares they represent.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).